A Study of Gene Variation and Response to Naproxen in Women with Heavy Menstrual Bleeding


About this study

The purpose of this study is to learn more about how individual women metabolize and respond to specific medications such as Naproxen and other NSAIDS. The way individuals metabolize NSAIDS may have a relationship to the effectiveness of Naproxen when used for treatment of heavy menstrual bleeding.


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Ppatients who received Naproxen therapy and have available 3 month data as part of the study “Initial Treatment for Women with Heavy Menstrual Bleeding”

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Hopkins, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer